# Novartis

Swiss pharma giant — Kymriah CAR-T pioneer and Cosentyx antibody blockbuster; large-scale biologics manufacturing across Basel and US sites.

Source: https://en.bioecon.ru/companies/novartis/
Updated: 2026-06-19

- Country: Switzerland
- Revenue: $52.7B
- Employees: ~78,000 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Production site | 33 manufacturing sites worldwide | https://prod1.novartis.com/sites/novartis_com/files/novartis-integrated-report-2024.pdf, https://www.novartis.com/ch-de/sites/novartis_ch/files/novartis-in-switzerland-2024.pdf |
| Headcount | 75,883 worldwide (2024) | https://www.novartis.com/ch-de/sites/novartis_ch/files/novartis-in-switzerland-2024.pdf |
| Certification | ISO 9001 certified; cGMP certified for all manufacturing operations | https://www.novartis.com/about/quality/novartis-quality-management-system-qms, https://www.novartis.com/sites/novartis_com/files/novartis-bsi-iso-9001-certificate-fs-771945.pdf |
| Regulatory approval | Regulated and inspected by authorities including FDA, EMA, WHO, and Swissmedic | https://www.novartis.com/about/quality/audit-program-and-regulatory-inspections, https://www.novartis.com/about/quality/novartis-quality-management-system-qms |
| Capacity | Large-scale biologics, CAR-T, RLT, and small molecule production capacity; 100% end-to-end US production goal by 2030 [medium confidence] | https://www.biopharmadive.com/news/novartis-car-t-kymriah-manufacturing-production-challenges/504017/, https://www.bioprocessintl.com/facilities-capacity/swiss-site-opens-to-boost-novartis-car-t-production, https://www.novartis.com/ch-de/sites/novartis_ch/files/novartis-in-switzerland-2024.pdf |
| Funding | $23 billion planned investment in US-based infrastructure (2025-2029) | https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years, https://www.sec.gov/Archives/edgar/data/1114448/000111444826000008/a260204-99_1.pdf |

Independent sources: biopharmadive.com, bioprocessintl.com, sec.gov

## Technologies

- [Biologics](https://en.bioecon.ru/technology/biologics/)
- [CAR-T cell therapy](https://en.bioecon.ru/technology/car-t-cell-therapy/)
- [Corporate biotech accelerators (JLABS, Bayer CoLaborator)](https://en.bioecon.ru/technology/corporate-biotech-accelerators/)
- [In-vivo gene therapy: AAV and lentiviral vectors](https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)
- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)
- [Radiopharmaceuticals & theranostics](https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/)